Just 61% of hospitals surveyed evaluated models for accuracy on their own data, and less than half evaluated the models for bias.
More hospitals need to assess predictive models for accuracy, bias: Health Affairs Read More »
Research has shown remnant cholesterol is a significant factor in cardiovascular disease risk.
Marea Posts Positive Phase II Data for Remnant Cholesterol Lowering mAb Read More »
Medtronic and Novo Holdings were among the investors in the funding round.
Fire1 raises $120M to trial heart failure management system Read More »
The Biotech Ecosystem Venture Fund will combine the sourcing capabilities of venture capital firm Andreessen Horowitz (a16z) with Eli Lilly’s expertise in R&D—plus half a billion in capital from the Big Pharma.
Lilly Partners With a16z on $500M VC Fund for Early-Stage Biotechs Read More »
After the successful development of mavacamten and the sale of MyoKardia to BMS in 2020, former executives of the biotech are back together with a mission to make cardiovascular disease curable and preventable.
MyoKardia Alumni Launch Kardigan with $300M to Tackle Heart Disease Read More »
Staff cuts could leave IGM Biosciences with fewer than 55 employees. The company is also halting development of two bispecific antibody T cell engagers for autoimmune diseases.
IGM Biosciences Lays Off 73% of Staff, Shrinks Pipeline Read More »
The law aims to close legal loopholes that officials say Steward Health Care exploited to keep regulators in the dark about its finances leading up to its bankruptcy.
After Steward crisis, new Massachusetts law aims to strengthen oversight of hospitals Read More »
Spencer’s arrival at Eko comes months after the digital health company appointed his former colleague Brent Lang to its board of directors.
Concurrently, a preprint from the industry-backed Vital Transformation found a 50% drop in company investments into small-molecule drug development.
Part D Drugs Almost Doubled in Cost Since Launch, Underscoring Importance of IRA: AARP Read More »
If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor indicated in combination with BCG for high-risk non-muscle invasive bladder cancer patients who had not previously undergone BCG treatment.
